The Future of "Liquid Biopsies" and Continuous Monitoring
The frontier of 2026 analytics is the integration of Liquid Biopsies and Remote Sensors. Clinical platforms can now monitor "circulating tumor DNA" (ctDNA) in the blood to detect cancer recurrence months before a tumor would show up on a CT scan.
When combined with data from wearable "Smart Patches" that track vitals 24/7, clinical analytics provides a continuous, longitudinal view of a patient’s health. This shift from "episodic" care (doctor visits) to "continuous" care allows for immediate intervention the moment a health parameter deviates from the norm, representing the ultimate realization of preventive medicine.
1 View
